Drug search by name

Esbriet and Hepatic impairment

Result of checking the interaction of drug Esbriet and disease Hepatic impairment for safety when used together.

Check result:

Esbriet <> Hepatic impairment

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Increases in ALT and AST (>3 x ULN) with or without concomitant elevations in bilirubin, have been reported in patients treated with pirfenidone. These findings were reversible with dose modification or treatment discontinuation. Conduct liver tests prior to therapy initiation in all patients, then monthly for the first 6 months and every 3 months thereafter. Dose modification or interruption may be necessary for liver enzyme elevations. Pirfenidone should be used with caution in patients with mild to moderate hepatic impairment, monitoring adverse reactions. The safety and efficacy of pirfenidone has not been studied in patients with severe hepatic impairment, and is not recommended for use in these patients.

Esbriet

Generic Name: pirfenidone

Brand Name: Esbriet

Synonyms: n.a.

What is Esbriet?